Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage

Summary

The overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury. Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot trial designed to obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent phase III trial.

Timeline

Start

2022-08-04

Primary completion

2024-12-03

Completion

2024-12-03

Publications

• Results Katsanos AH, Ng KKH, Field TS, Ganesh A, Schaafsma JD, Jalini S, Shuaib A, Mai LM, Yu AYX, Gioia LC, Cooley R, Dowlatshahi D, Srivastava A, Tsivgoulis G, Wang A, Balasubramanian K, Reeh KW, Taylor A, Hart RG, Shoamanesh A. Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage: A Placebo-Controlled Trial. Stroke. 2026 Aug 6. doi: 10.1161/STROKEAHA.126.055934. Online ahead of print.
• Wilkinson CM, Katsanos AH, Sander NH, Kung TFC, Colbourne F, Shoamanesh A. Colchicine pre-treatment and post-treatment does not worsen bleeding or functional outcome after collagenase-induced intracerebral hemorrhage. PLoS One. 2022 Oct 18;17(10):e0276405. doi: 10.1371/journal.pone.0276405. eCollection 2022.

Drugs

Indications